ライフサイエンスコーパス: PPHN

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 y regulated during both lung development and PPHN.

2 maternal use of SSRIs in late pregnancy and PPHN in the offspring; further study of this association

3 ulature; the possible link between SSRIs and PPHN; and the diagnosis, clinical management, and progno

4 Associations between antidepressant use and PPHN were attenuated with increasing levels of confoundi

5 In the current classification, PPHN is now designated number 1.

6 ther than SSRI exposure as a risk factor for PPHN.

7 n response to common clinical treatments for PPHN, such as oxygen and inhaled NO.

8 003, we enrolled 377 women whose infants had PPHN and 836 matched control women and their infants.

9 ambs with persistent pulmonary hypertension (PPHN) after prenatal ligation of the ductus arteriosus.

10 ambs with persistent pulmonary hypertension (PPHN) following prenatal ligation of the ductus arterios

11 ants with persistent pulmonary hypertension (PPHN).

12 iglets both during normal development and in PPHN.

13 Systemic oxygenation was impaired in PPHN lambs and significantly improved (up to threefold)

14 stent pulmonary hypertension of the newborn (PPHN) are often mechanically ventilated with high oxygen

15 stent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more diff

16 stent pulmonary hypertension of the newborn (PPHN) has been controversial since the US Food and Drug

17 stent pulmonary hypertension of the newborn (PPHN) is associated with substantial infant mortality an

18 stent pulmonary hypertension of the newborn (PPHN) remains a significant cause of neonatal morbidity

19 stent pulmonary hypertension of the newborn (PPHN), a potentially serious but rare respiratory illnes

20 stent pulmonary hypertension of the newborn (PPHN), NO-mediated dilation is dysfunctional.

21 Recorded diagnosis of PPHN during the first 30 days after delivery.

22 litates the action of iNO in a lamb model of PPHN.

23 nosis, clinical management, and prognosis of PPHN.

24 onsistent with a potential increased risk of PPHN associated with maternal use of SSRIs in late pregn

25 third trimester of pregnancy and the risk of PPHN in the infant.

26 ncy was associated with an increased risk of PPHN.

27 1 may prove to be useful in the treatment of PPHN.

28 Upon restriction of the outcome to primary PPHN, the adjusted odds ratio for SSRIs was 1.28 (95% CI

29 w summarizes the current knowledge regarding PPHN pathophysiology, including the role of serotonin an

30 apy with iNO and PGI2 in infants with severe PPHN.

31 Twenty-six PPHN lambs were ventilated for 24 h with 100% O(2) alone

32 orm expression may be a mechanism underlying PPHN.

33 ormed a case-control study to assess whether PPHN is associated with exposure to SSRIs during late pr

34 posed to antidepressants were diagnosed with PPHN (20.8; 95% CI, 20.4-21.3 per 10,000 births) compare

35 Fourteen infants with PPHN had been exposed to an SSRI after the completion of

36 als of rhSOD and iNO in newborn infants with PPHN.

37 erning inhaled nitric oxide for infants with PPHN.

38 Six newborn lambs with PPHN (induced by antenatal ductal ligation) were killed

39 studies were performed in newborn lambs with PPHN to study the vascular effects of E4021 alone, and i

40 triction and oxidation in newborn lambs with PPHN.

41 mpared with nonventilated newborn lambs with PPHN.

42 pulmonary arteries isolated from lambs with PPHN.

43 We present the first case of a neonate with PPHN treated concurrently with inhaled nitric oxide (iNO

44 inhalation has been tested in newborns with PPHN, congenital heart diseases, and bronchopulmonary dy

45 ctive adjunctive treatment for newborns with PPHN.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。